QRG Capital Management Inc. Boosts Stake in Haleon PLC Sponsored ADR $HLN

QRG Capital Management Inc. grew its holdings in shares of Haleon PLC Sponsored ADR (NYSE:HLN) by 17.4% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 379,517 shares of the company’s stock after acquiring an additional 56,362 shares during the period. QRG Capital Management Inc.’s holdings in Haleon were worth $3,799,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the business. Norges Bank acquired a new position in shares of Haleon in the fourth quarter worth about $163,529,000. Natixis Advisors LLC grew its stake in Haleon by 429.8% during the 4th quarter. Natixis Advisors LLC now owns 10,003,941 shares of the company’s stock valued at $101,140,000 after purchasing an additional 8,115,633 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its stake in Haleon by 4,315.4% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 8,027,189 shares of the company’s stock valued at $81,155,000 after purchasing an additional 7,845,391 shares in the last quarter. Bank of Montreal Can increased its holdings in Haleon by 454.1% during the 4th quarter. Bank of Montreal Can now owns 8,500,496 shares of the company’s stock worth $85,940,000 after purchasing an additional 6,966,416 shares during the last quarter. Finally, Bank of America Corp DE increased its holdings in Haleon by 116.7% during the 2nd quarter. Bank of America Corp DE now owns 12,384,135 shares of the company’s stock worth $128,423,000 after purchasing an additional 6,669,923 shares during the last quarter. 6.67% of the stock is currently owned by institutional investors and hedge funds.

Haleon Stock Down 0.2%

NYSE:HLN opened at $9.80 on Monday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.71 and a current ratio of 0.92. The company has a market capitalization of $43.22 billion, a price-to-earnings ratio of 25.14, a price-to-earnings-growth ratio of 2.29 and a beta of 0.13. Haleon PLC Sponsored ADR has a one year low of $8.65 and a one year high of $11.28. The stock has a 50-day simple moving average of $9.17 and a 200 day simple moving average of $9.87.

Haleon (NYSE:HLN) last announced its quarterly earnings data on Saturday, February 14th. The company reported $6.32 earnings per share (EPS) for the quarter. The firm had revenue of $3.65 billion for the quarter. Sell-side analysts predict that Haleon PLC Sponsored ADR will post 0.55 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Argus raised Haleon to a “strong-buy” rating in a research report on Tuesday, March 17th. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Haleon in a research report on Thursday, April 30th. Wall Street Zen lowered shares of Haleon from a “buy” rating to a “hold” rating in a research note on Saturday. Rothschild & Co Redburn cut shares of Haleon from a “strong-buy” rating to a “hold” rating in a report on Tuesday, June 16th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Haleon in a research note on Tuesday, June 30th. Two research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy”.

Haleon Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.